Abstract
1. Regulation of dopamine transporter (DAT) mRNA was studied in rats treated with the DAT blocker bupropion (BUP; 15 or 30 mg/kg tid x 2d), the norepinephrine transporter blocker desipramine (DMI; 10 mg/kg/d x 2d), or saline. 2. mRNA expression was assessed via in situ hybridization histochemistry. 3. BUP and DMI both increased DAT mRNA expression in the ventral tegmental area/substantia nigra. 4. These findings suggest that DAT mRNA expression in the brain may be regulated by both noradrenergic and dopaminergic mechanisms.
Publication types
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Antidepressive Agents, Second-Generation / pharmacology*
-
Antidepressive Agents, Tricyclic / pharmacology*
-
Autoradiography
-
Brain Chemistry / drug effects*
-
Bupropion / pharmacology*
-
Carrier Proteins / biosynthesis*
-
Desipramine / pharmacology*
-
Dopamine Plasma Membrane Transport Proteins
-
Dose-Response Relationship, Drug
-
In Situ Hybridization
-
Male
-
Membrane Glycoproteins*
-
Membrane Transport Proteins*
-
Nerve Tissue Proteins*
-
RNA Probes
-
RNA, Messenger / biosynthesis*
-
Rats
-
Rats, Sprague-Dawley
-
Ventral Tegmental Area / drug effects
-
Ventral Tegmental Area / metabolism*
Substances
-
Antidepressive Agents, Second-Generation
-
Antidepressive Agents, Tricyclic
-
Carrier Proteins
-
Dopamine Plasma Membrane Transport Proteins
-
Membrane Glycoproteins
-
Membrane Transport Proteins
-
Nerve Tissue Proteins
-
RNA Probes
-
RNA, Messenger
-
Slc6a3 protein, rat
-
Bupropion
-
Desipramine